After receiving more than 100 applications, NASA’s Jet Propulsion Laboratory (JPL) in Southern California has selected eight U.S. manufacturers to make a new ventilator tailored for coronavirus (COVID-19) patients.

The prototype, which was created by JPL engineers in just 37 days, received an Emergency Use Authorization from the Food and Drug Administration on April 30.

Called VITAL (Ventilator Intervention Technology Accessible Locally), the high-pressure ventilator was designed to use one-seventh the parts of a traditional ventilator, relying on parts already available in supply chains. It offers a simpler, more affordable option for treating critical patients while freeing up traditional ventilators for those with the most severe COVID-19 symptoms. Its flexible design means it also can be modified for use in field hospitals.

The Office of Technology Transfer and Corporate Partnerships at Caltech, which owns the patents and software for VITAL, is offering a free license for the device. Caltech manages JPL for NASA.

“The VITAL team is very excited to see their technology licensed,” said Leon Alkalai, manager of the JPL Office of Strategic Partnerships and a member of the VITAL leadership team. “Our hope is to have this technology reach across the world and provide an additional source of solutions to deal with the on-going COVID-19 crisis.”

JPL now is evaluating international manufacturers from countries as diverse as Brazil, Mexico, India and Malaysia. The 3 approved manufacturers from India are  Alpha Design Technologies Pvt Ltd, Bharat Forge Ltd and Medha Servo Drives Pvt Ltd. , the US space agency said in a statement on Friday.

The prototype, which was created by NASA’s Jet Propulsion Laboratory engineers in just 37 days, received an emergency use authorisation from the US Food and Drug Administration on April 30.

Called VITAL (Ventilator Intervention Technology Accessible Locally), the high-pressure ventilator was designed to use one-seventh the parts of a traditional ventilator, relying on parts already available in the supply chains. It offers a simpler, more affordable option for treating critical patients while freeing up traditional ventilators for those with the most severe COVID-19 symptoms.

NASA has so far selected 21 companies – eight US companies and 13 international companies (including three from India) to make the ventilator developed with inputs from doctors and medical device manufacturers.